Climb Bio Stock Price, News & Analysis

Climb Bio (NASDAQ: CLYM) has granted an inducement equity award to a new employee under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The award, granted on May 19, 2025, consists of a non-statutory stock option to purchase 120,000 shares of common stock at an exercise price of $1.27 per share, matching the closing price on Nasdaq Global Market. The option has a ten-year term and vests over four years, with 25% vesting after the first year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.

Climb Bio (NASDAQ: CLYM) reported its Q1 2025 financial results and provided key business updates. The company's lead program budoprutug, an anti-CD19 monoclonal antibody, is advancing with FDA clearances for clinical trials in multiple indications. Clinical studies for ITP and SLE are set to begin in H1 2025, followed by pMN trials in H2 2025.

The company expanded its pipeline with CLYM116, an anti-APRIL monoclonal antibody licensed from Mabworks for IgA nephropathy treatment. Climb Bio strengthened its leadership by appointing two new independent directors and a Chief Business Officer. Financially, the company reported $197.8 million in cash and equivalents, expected to fund operations through 2027. R&D expenses increased to $17.3 million in Q1 2025, including a $9.0 million upfront payment to Mabworks.

Climb Bio (Nasdaq: CLYM) has announced significant changes to its Board of Directors with the appointments of two biotech industry veterans: Kim Cobleigh Drapkin, CPA, and Bo Cumbo. Drapkin, who will serve as Audit Committee Chair, brings over 30 years of financial leadership experience in biotech and pharmaceutical companies, most recently serving as CEO of Graphite Bio.

Cumbo, appointed as Compensation Committee Chair, has 30+ years of experience in the pharmaceutical and biotechnology industries, with a track record of leading 11 successful specialty and rare disease therapy launches. He currently serves as President and CEO of Solid Biosciences.

The appointments come as Climb Bio positions itself for evolution into a late-stage, pre-commercial company focused on immune-mediated diseases. Concurrent with these appointments, Simon Tate will step down from the Board, and Adam Rosenberg will not seek re-election at the 2025 Annual Meeting.

Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's executive team will be presenting at this virtual event, which is scheduled to take place from April 7-10, 2025.

The presentation is specifically scheduled for April 10, 2025, at 8:45 a.m. ET. The format will include both a formal presentation and one-on-one investor meetings, providing opportunities for direct engagement with the company's leadership.

Climb Bio (NASDAQ: CLYM) reported its Q4 and full-year 2024 financial results, marking significant progress in its immune-mediated disease therapeutics pipeline. The company secured FDA clearance for clinical trials of budoprutug in three indications: Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE).

The company expanded its pipeline by in-licensing CLYM116, an anti-APRIL monoclonal antibody for IgA Nephropathy treatment. Financial highlights include a strong cash position of $212.5 million as of December 31, 2024, expected to fund operations through 2027. The company reported a net loss of $73.9 million for full-year 2024, compared to $35.1 million in 2023, with the increase primarily due to $51.7 million in acquired research and development expenses.

Climb Bio (Nasdaq: CLYM) announced that its executive team will participate in two upcoming investor conferences in March 2025. The company will attend the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 a.m. ET, featuring a formal presentation and one-on-one investor meetings. A webcast link is provided for virtual attendance.

Additionally, Climb Bio will participate in Leerink's Global Healthcare Conference 2025 on March 10, 2025, at 10:00 a.m. ET. This event will include a fireside chat format and one-on-one investor meetings, with a webcast link also available. The announcement was made from the company's Wellesley, Massachusetts headquarters on February 25, 2025.

Climb Bio (NASDAQ: CLYM) has appointed Dr. Perrin Wilson as Chief Business Officer. With 17 years of pharmaceutical and biotech industry experience, Dr. Wilson will lead the company's pre-commercial planning, communications, and business development efforts. Prior to joining Climb Bio, she served as Senior Vice President of Business Development and Strategy at Nuvalent and held key positions at Forma Therapeutics/Novo Nordisk.

Dr. Wilson's notable achievements include leading Forma's $1.1 billion acquisition by Novo Nordisk and Takeda's $5.2 billion acquisition of ARIAD. At Climb Bio, she will focus on advancing the company's pipeline, including key assets budoprutug and CLYM116, aimed at developing treatments for immune-mediated diseases.

Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company's executive team will deliver a presentation on February 12, 2025, at 9:20 a.m. ET.

The virtual conference will feature both a formal presentation and one-on-one investor meetings. The event provides an opportunity for investors and stakeholders to gain insights into Climb Bio's developments and strategic initiatives.

Climb Bio (NASDAQ: CLYM) has secured an exclusive license agreement with Beijing Mabworks Biotech for CLYM116, an anti-APRIL monoclonal antibody, for development and commercialization outside Greater China. The agreement focuses on treating IgA nephropathy, the most common form of glomerulonephritis worldwide.

CLYM116 is engineered to prevent APRIL signaling through a novel mechanism, potentially offering advantages over current APRIL-targeted therapeutics. The company will make a $9 million upfront payment to Mabworks, with additional milestone payments and low- to mid-single digit tiered royalties on net sales.

The company reported $212.9 million in cash and equivalents as of December 31, 2024, expecting to fund operations through 2027. Initial preclinical data for CLYM116 is anticipated later in 2025.